G1 Therapeutics, Inc. (GTHX): Price and Financial Metrics
GTHX Price/Volume Stats
| Current price | $3.99 | 52-week high | $5.00 |
| Prev. close | $3.86 | 52-week low | $1.08 |
| Day low | $3.84 | Volume | 441,500 |
| Day high | $4.05 | Avg. volume | 1,280,485 |
| 50-day MA | $3.72 | Dividend yield | N/A |
| 200-day MA | $2.62 | Market Cap | 208.41M |
GTHX Stock Price Chart Interactive Chart >
G1 Therapeutics, Inc. (GTHX) Company Bio
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. The company was founded in 2008 and is based in Research Triangle Park, North Carolina.
Latest GTHX News From Around the Web
Below are the latest news stories about G1 THERAPEUTICS INC that investors may wish to consider to help them evaluate GTHX as an investment opportunity.
Insider Sell Alert: Chief Medical Officer Rajesh Malik Offloads Shares of G1 Therapeutics IncIn a notable insider transaction, Chief Medical Officer Rajesh Malik has sold a significant number of shares in G1 Therapeutics Inc (NASDAQ:GTHX), a clinical-stage biopharmaceutical company. |
G1 Therapeutics (NASDAQ:GTHX) adds US$67m to market cap in the past 7 days, though investors from five years ago are still down 90%This month, we saw the G1 Therapeutics, Inc. ( NASDAQ:GTHX ) up an impressive 103%. But will that heal all the wounds... |
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy- Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial Indicate That Prior Use of Trilaciclib with Cytotoxic Chemotherapy is Highly Correlated to Improved Long-Term Survival with Subsequent Anticancer Therapies - - Improved Long-Term Survival Also Observed in Patients Who Received Prior Trilaciclib with Cytotoxic Therapy and Were Unable to Receive Subsequent Anticancer Therapy - - Data Presented at the 2023 San Antonio Breast Cancer Symposium (SABCS |
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 4,700 shares of G1’s common stock and 2,300 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to th |
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer SymposiumRESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer (mTNBC) from the Company’s Phase 2 trial (NCT02978716) will be presented in a poster session during the upcoming 2023 San Antonio Breast Cancer Symposium (SABCS), held December 5th through 9th in San Ant |
GTHX Price Returns
| 1-mo | N/A |
| 3-mo | 5.28% |
| 6-mo | 197.76% |
| 1-year | 39.02% |
| 3-year | -81.06% |
| 5-year | -80.53% |
| YTD | 30.82% |
| 2023 | -43.83% |
| 2022 | -46.82% |
| 2021 | -43.25% |
| 2020 | -31.93% |
| 2019 | 38.02% |
Loading social stream, please wait...